Estrella Immunopharma (ESLA) Competitors $1.16 +0.06 (+5.45%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ESLA vs. KYTX, MDWD, SGMT, HURA, CRBP, CRBU, DRUG, STRO, ACTU, and TSVTShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Kyverna Therapeutics (KYTX), MediWound (MDWD), Sagimet Biosciences (SGMT), TuHURA Biosciences (HURA), Corbus Pharmaceuticals (CRBP), Caribou Biosciences (CRBU), Bright Minds Biosciences (DRUG), Sutro Biopharma (STRO), Actuate Therapeutics (ACTU), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Kyverna Therapeutics MediWound Sagimet Biosciences TuHURA Biosciences Corbus Pharmaceuticals Caribou Biosciences Bright Minds Biosciences Sutro Biopharma Actuate Therapeutics 2seventy bio Kyverna Therapeutics (NASDAQ:KYTX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Is KYTX or ESLA more profitable? Kyverna Therapeutics' return on equity of -51.12% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Estrella Immunopharma N/A -195.77%-157.28% Does the media favor KYTX or ESLA? In the previous week, Kyverna Therapeutics had 38 more articles in the media than Estrella Immunopharma. MarketBeat recorded 38 mentions for Kyverna Therapeutics and 0 mentions for Estrella Immunopharma. Kyverna Therapeutics' average media sentiment score of 0.09 beat Estrella Immunopharma's score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Kyverna Therapeutics Neutral Estrella Immunopharma Neutral Which has preferable earnings & valuation, KYTX or ESLA? Estrella Immunopharma has lower revenue, but higher earnings than Kyverna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M24.56-$60.37MN/AN/AEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-4.46 Does the MarketBeat Community prefer KYTX or ESLA? Kyverna Therapeutics received 10 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1066.67% Underperform Votes533.33% Estrella ImmunopharmaN/AN/A Do analysts recommend KYTX or ESLA? Kyverna Therapeutics presently has a consensus price target of $25.71, indicating a potential upside of 542.86%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kyverna Therapeutics is more favorable than Estrella Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in KYTX or ESLA? 18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryKyverna Therapeutics beats Estrella Immunopharma on 11 of the 13 factors compared between the two stocks. Ad Porter & CompanyFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.I share with you in this special investigative documentary. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.80M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-4.4646.7391.4117.18Price / SalesN/A411.851,113.72116.79Price / CashN/A182.1042.7137.86Price / Book9.673.894.794.78Net Income-$7.31M-$42.21M$120.07M$225.60M7 Day Performance-2.82%-2.15%-1.92%-1.23%1 Month Performance28.18%4.20%11.46%3.36%1 Year Performance-6.45%18.39%30.49%16.59% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma0.1528 of 5 stars$1.16+5.5%N/A-7.2%$39.80MN/A-4.46N/AGap DownKYTXKyverna Therapeutics2.4277 of 5 stars$4.24-4.1%$25.71+506.5%N/A$183.05M$7.03M0.0096News CoverageMDWDMediWound1.9097 of 5 stars$16.75-3.1%$27.50+64.2%+58.3%$180.67M$19.72M-5.9380Positive NewsGap DownSGMTSagimet Biosciences2.3293 of 5 stars$5.73+30.5%$23.00+301.4%-8.0%$175.74M$2M0.008Gap UpHigh Trading VolumeHURATuHURA BiosciencesN/A$4.14-16.0%$15.00+262.3%N/A$175.06MN/A0.00N/AAnalyst ForecastNews CoverageCRBPCorbus Pharmaceuticals3.9067 of 5 stars$14.28-5.3%$62.00+334.2%+147.6%$173.93M$880,000.00-3.2240CRBUCaribou Biosciences2.2028 of 5 stars$1.91flat$10.20+434.0%-69.4%$172.96M$11.48M-1.16100DRUGBright Minds Biosciences3.5828 of 5 stars$38.82-5.3%$75.00+93.2%+2,621.8%$172.13MN/A-60.29N/ANews CoverageGap UpSTROSutro Biopharma4.4663 of 5 stars$2.07-2.4%$11.13+437.4%-51.3%$170.69M$153.73M-1.29240High Trading VolumeACTUActuate TherapeuticsN/A$8.69+0.8%N/AN/A$169.73MN/A0.0010Gap UpTSVT2seventy bio2.2166 of 5 stars$3.26-0.3%$9.00+176.1%-7.1%$168.18M$100.39M-1.76440Positive News Related Companies and Tools Related Companies Kyverna Therapeutics Competitors MediWound Competitors Sagimet Biosciences Competitors TuHURA Biosciences Competitors Corbus Pharmaceuticals Competitors Caribou Biosciences Competitors Bright Minds Biosciences Competitors Sutro Biopharma Competitors Actuate Therapeutics Competitors 2seventy bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESLA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.